Valuation: AbbVie Inc.

Market Cap 442B 404,209B 382B 358B 326B 614B 42,296B 622B 4,200B 1,646B 21,190B 1,661B 1,625B 70,488B P/E 2026 *
32x
P/E 2027 * 23.6x
Enterprise Value 503B 459,482B 434B 407B 371B 697B 48,079B 707B 4,774B 1,871B 24,088B 1,888B 1,847B 80,127B EV / Sales 2026 *
7.44x
EV / Sales 2027 * 6.72x
Free-Float
95.71%
Yield 2026 *
2.74%
Yield 2027 * 2.88%
1 week+0.23%
Current month-6.25%
1 month+32.41%
3 months+32.41%
6 months+32.41%
Current year+32.41%
1 week 227,210
Extreme 227210
227,210
1 month 171,590
Extreme 171590
242,370
Current year 171,590
Extreme 171590
242,370
1 year 171,590
Extreme 171590
242,370
3 years 165,000
Extreme 165000
242,370
5 years 165,000
Extreme 165000
242,370
10 years 165,000
Extreme 165000
242,370
Manager TitleAgeSince
Chief Executive Officer 55 2024-06-30
Director of Finance/CFO 59 2022-06-22
Chief Tech/Sci/R&D Officer - 2024-02-29
Director TitleAgeSince
Director/Board Member 65 2012-12-31
Director/Board Member 74 2012-12-31
Director/Board Member 69 2012-12-31
Change 5-day change 1-year change 3-year change Capi.($)
0.00%+0.23% - - 442B
+0.25%-3.96%+68.73%+120.06% 1,055B
+0.78%+0.21%+48.53%+50.78% 632B
+0.35%+0.95%+21.11%+66.86% 442B
+0.28%-4.56%+39.10%+38.05% 351B
+0.78%-2.68%+24.03%+37.32% 290B
+0.87%-3.59%-0.28%+7.12% 243B
+1.00%+0.52%+41.46%+58.95% 227B
-0.78%-4.49%-10.28%-54.13% 200B
+0.40%+4.40%+17.36%+81.59% 172B
Average +0.39%-1.44%+27.75%+45.18% 401.39B
Weighted average by Cap. +0.39%-1.87%+39.71%+63.88%

Financials

2026 *2027 *
Net sales 67.58B 61,756B 58.35B 54.74B 49.86B 93.74B 6,462B 95.04B 642B 251B 3,237B 254B 248B 10,769B 73.52B 67,178B 63.47B 59.54B 54.23B 102B 7,029B 103B 698B 274B 3,522B 276B 270B 11,715B
Net income 13.86B 12,666B 11.97B 11.23B 10.23B 19.23B 1,325B 19.49B 132B 51.57B 664B 52.04B 50.92B 2,209B 18.91B 17,283B 16.33B 15.32B 13.95B 26.23B 1,808B 26.6B 180B 70.37B 906B 71.01B 69.47B 3,014B
Net Debt 60.49B 55,273B 52.22B 48.99B 44.62B 83.9B 5,784B 85.07B 574B 225B 2,898B 227B 222B 9,639B 51.66B 47,205B 44.6B 41.84B 38.11B 71.66B 4,939B 72.65B 490B 192B 2,475B 194B 190B 8,232B
Logo AbbVie Inc.
AbbVie Inc. specializes in therapeutic drug research and development. Its products are intended for treating rheumatoid arthritis, psoriasis, Crohn's disease, thyroid disease, Parkinson's disease, HIV, complications of mucoviscidosis, low testosterone levels, and complications associated with chronic renal disease. Net sales are distributed geographically as follows: the United States (76.2%), Germany (2.8%), Japan (2.1%), Canada (2%), China (1.6%), France (1.3%), the United Kingdom (1%), Spain (1%), Italy (0.9%), Brazil (0.8%), Australia (0.8%), and Other (9.5%).
Employees
57,000
Date Price Change
26-08-17 CLP 227,210.00 0.00%
26-08-14 CLP 227,210.00 0.00%
26-08-13 CLP 227,210.00 0.00%
26-08-12 CLP 227,210.00 0.00%
26-08-11 CLP 227,210.00 +0.23%
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
31
Last Close Price
250.33USD
Average target price
276.41USD
Spread / Average Target
+10.42%

Quarterly revenue - Rate of surprise